About CisGEN
CisGEN is a Healthcare company based in Chennai (India) founded in 2017 by Maroudam Veerasamy. Its Indian entity Cisgen Biotech Discoveries Private Limited reported revenue of ₹2.62 Cr. Its focus areas include HealthTech, Veterinary HealthTech, In Vitro Diagnostics and Diversified.
Company details
Provider of novel therapeutics products and services for animal health. patents-pending bio-therapeutic solutions against the infectious diseases of pets and livestock. The company offers the products like Parvoguard which is a patented feed supplement for puppies against canine parvoviral; SmartEasy which is an AI-based device and the integrated app that helps in data retrieval and point of care diagnostics kits for animal diseases like Pen-side kits for animal disease diagnosis.
- Headquarters Chennai, India
- Founders Maroudam Veerasamy
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website cisgenbiotech.com
- Social LinkedIn
- Legal Name Cisgen Biotech Discoveries Private Limited
- Date of Incorporation 07 Mar, 2017
- Jurisdiction Chennai, Tamil Nadu, India
- Annual Revenue₹2.62 Cr
FY 2024 · +61% YoY
- Net Profit₹12.5 Lakh
FY 2024 · 5% margin
- EBITDA₹20.9 Lakh
FY 2024 · 8% margin
- Investors
Associated legal entities of CisGEN
CisGEN operates through Cisgen Biotech Discoveries Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Cisgen Biotech Discoveries Private Limited CIN U73100TN2017PTC115332 | Active | 07 Mar 2017 | Chennai, Tamil Nadu | ₹2.6 Cr | 2 | View details |
Funding Insights of CisGEN
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of CisGEN with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2019 | Seed | – | BIRAC | – |
1 investors in total: 1 institutional.
Investors in CisGEN
CisGEN has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include BIRAC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Business incubation services are provided across multiple sectors. | birac.nic.in | Delhi, India |
Investor details for CisGEN
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Cisgen Biotech Discoveries Private Limited (CisGEN)
Cisgen Biotech Discoveries Private Limited is the primary company behind CisGEN. The board of Cisgen Biotech Discoveries Private Limited currently have 2 directors; the longest-serving is Maroudam Veerasamy, appointed in 2017. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Maroudam Veerasamy DIN 07701031 | Director | 07 Mar 2017 | 9 yrs 8 mo | Cisgen Biotech Discoveries Private Limited |
| Muthu Kumar Gopalan DIN 06926065 | Director | 01 Jul 2020 | 6 yrs 4 mo | Cisgen Biotech Discoveries Private Limited |
People of CisGEN
1 people are tracked at CisGEN (1 in leadership).
| Name | Role | Group |
|---|---|---|
| Founder | Leadership |
Complete people profiles for CisGEN
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of CisGEN
Figures of Cisgen Biotech Discoveries Private Limited, the primary company behind CisGEN, for FY 2024. Revenue was ₹2.62 Cr (+61% year on year). Net profit was ₹12.5 Lakh (5% margin). EBITDA was ₹20.9 Lakh (8% margin). Revenue has grown at a compounded annual rate of +14% over three years and +37% over five years.
- ₹2.62 CrRevenue · FY 2024 · +61% YoY
- ₹12.5 LakhNet profit · 5% margin
- ₹20.9 LakhEBITDA · 8% margin
- ₹1.3 LakhPaid-up capital
- +14%Revenue CAGR, 3 years
- +37%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Cisgen Biotech Discoveries Private Limited are on its company page.
Detailed financial statements for CisGEN
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of CisGEN
2 dated milestones of CisGEN across 2 years, from founding to its latest funding, stage changes and deals.
- Founded CisGEN is founded.
- Funding First funding round.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Articles about CisGEN on our blog
- Startups awarded for animal husbandry29 May 2020
Frequently Asked Questions about CisGEN
CisGEN was founded in 2017 and raised its 1st funding round 2 years after it was founded.
CisGEN is headquartered in Chennai, India. It is registered at Chennai, Tamil Nadu, India.
The primary company behind CisGEN, Cisgen Biotech Discoveries Private Limited, reported revenue of ₹2.62 Cr for FY 2024, up 61% year on year.
Provider of novel therapeutics products and services for animal health. patents-pending bio-therapeutic solutions against the infectious diseases of pets and livestock. The company offers the products like Parvoguard which is a patented feed supplement for puppies against canine parvoviral; SmartEasy which is an AI-based device and the integrated app that helps in data retrieval and point of care diagnostics kits for animal diseases like Pen-side kits for animal disease diagnosis.
CisGEN has 1 investor. Key investors include BIRAC.
CisGEN operates through Cisgen Biotech Discoveries Private Limited.
The legal entities of CisGEN currently have 2 directors, including Muthu Kumar Gopalan, Maroudam Veerasamy.